1.GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
This study is ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier: NCT00480025
The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor, by measuring Disease Free Survival.
2.Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
ClinicalTrials.gov Identifier: NCT00324805
This randomized phase III trial is studying chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery.
Hospital Charles Lemoyne, Greenfield Park
McGill Cancer Centre at McGill University, Montreal
Allan Blair Cancer Centre at Pasqua Hospital, Regina
Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon
Cross Cancer Institute, Edmonton
Cancer Care Manitoba, Winnipeg
Moncton Hospital, Moncton
Cancer Care NS, Halifax
Princess Margaret Hospital, Toronto
London regional Cancer Center, London
Algoma District Cancer Program at Sault Area Hospital, Sault Ste Marie
Northeastern Ontario Regional Cancer Centre, Sudbury
Cancer Care Program at Thunder Bay Regional Health Sciences, Thunder Bay
Ottawa Regional Cancer Program, Ottawa
Royal Victoria Hospital,
Trillium Health Center,
BCCA, Vancouver Center